伏立康唑负载脂质纳米粒子用于眼科递送:使用QbD结合基于风险的方法开发

Q3 Medicine
Akanksha Patel, A. Dharamsi
{"title":"伏立康唑负载脂质纳米粒子用于眼科递送:使用QbD结合基于风险的方法开发","authors":"Akanksha Patel, A. Dharamsi","doi":"10.2174/2468187313666230420075952","DOIUrl":null,"url":null,"abstract":"\n\nVoriconazole (VRZ) is widely used for fungal keratitis topically. It is sparingly water soluble and has limited permeability which can lead to poor bioavailability. Nanostructured Lipid Carriers (NLCs) are selected as a carrier for voriconazole as they increase solubility\nwhile the lipidic character of the formulation facilitates permeation.\n\n\n\no To develop a new method of preparation of lipidic nanoparticles\no To apply Quality by design and risk-based approach to find variables\no To optimize variables and find the design space\no To evaluate and characterize the optimized formulation\n\n\n\nThe present study is an attempt to address the challenges in the formulation of NLCs using a high-speed homogenizer. Quality by Design approach was used to find the material attributes\nand process parameters playing a significant role in the formulation development. Quality Target\nproduct profile was prepared, and failure mode and effect analysis was performed for a better understanding of the risks, ways to alleviate risks, and finally, to propose a control strategy. The formulation was optimized by using 3-levels 3-factors central composite design, and design space was\nobtained by using graphical optimization. The morphology of the particles was studied by using\nTransmission Electron Microscope. In vitro drug release study was performed using Franz diffusion\ncell.\n\n\n\nThe amount of solid lipid, solid lipid to total lipid ratio, and concentration of surfactant\nwere found to be high risk variables and their effects on the product quality were examined using\nCentral composite design considering particle size, particle size distribution and %entrapment\nefficiency as dependent variables. Optimized NLC had a particle size of 72.58 nm with PDI 0.137\nand %entrapment efficiency of 78.79%. The in vitro drug release study showed sustained drug\nrelease over the period of 24 hrs and followed the Higuchi model with a fickian diffusion mechanism\n\n\n\nThe present study successfully explored QbD along with Risk-based approach for the\ndevelopment of voriconazole containing lipidic nanoparticles.\n","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Voriconazole Loaded Lipidic Nanoparticles for Ophthalmic Delivery: Development Using QbD Combined with Risk-based Approach\",\"authors\":\"Akanksha Patel, A. Dharamsi\",\"doi\":\"10.2174/2468187313666230420075952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nVoriconazole (VRZ) is widely used for fungal keratitis topically. It is sparingly water soluble and has limited permeability which can lead to poor bioavailability. Nanostructured Lipid Carriers (NLCs) are selected as a carrier for voriconazole as they increase solubility\\nwhile the lipidic character of the formulation facilitates permeation.\\n\\n\\n\\no To develop a new method of preparation of lipidic nanoparticles\\no To apply Quality by design and risk-based approach to find variables\\no To optimize variables and find the design space\\no To evaluate and characterize the optimized formulation\\n\\n\\n\\nThe present study is an attempt to address the challenges in the formulation of NLCs using a high-speed homogenizer. Quality by Design approach was used to find the material attributes\\nand process parameters playing a significant role in the formulation development. Quality Target\\nproduct profile was prepared, and failure mode and effect analysis was performed for a better understanding of the risks, ways to alleviate risks, and finally, to propose a control strategy. The formulation was optimized by using 3-levels 3-factors central composite design, and design space was\\nobtained by using graphical optimization. The morphology of the particles was studied by using\\nTransmission Electron Microscope. In vitro drug release study was performed using Franz diffusion\\ncell.\\n\\n\\n\\nThe amount of solid lipid, solid lipid to total lipid ratio, and concentration of surfactant\\nwere found to be high risk variables and their effects on the product quality were examined using\\nCentral composite design considering particle size, particle size distribution and %entrapment\\nefficiency as dependent variables. Optimized NLC had a particle size of 72.58 nm with PDI 0.137\\nand %entrapment efficiency of 78.79%. The in vitro drug release study showed sustained drug\\nrelease over the period of 24 hrs and followed the Higuchi model with a fickian diffusion mechanism\\n\\n\\n\\nThe present study successfully explored QbD along with Risk-based approach for the\\ndevelopment of voriconazole containing lipidic nanoparticles.\\n\",\"PeriodicalId\":10818,\"journal\":{\"name\":\"Current Nanomedicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Nanomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2468187313666230420075952\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Nanomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2468187313666230420075952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

伏立康唑(VRZ)广泛用于真菌性角膜炎的局部治疗。它是微水溶性的,并且具有有限的渗透性,这可能导致较差的生物利用度。纳米结构脂质载体(NLCs)被选为伏立康唑的载体,因为它们增加了溶解度,同时制剂的脂质特性促进了渗透。o开发一种制备脂质纳米粒子的新方法,应用设计质量和基于风险的方法来寻找变量o优化变量并找到设计空间o评估和表征优化配方本研究试图解决使用高速均质器配制NLCs的挑战。采用设计质量法来寻找在配方开发中发挥重要作用的材料特性和工艺参数。编制了质量目标产品简介,并进行了故障模式和影响分析,以更好地了解风险、缓解风险的方法,最后提出控制策略。采用三级三因素中心组合设计对配方进行了优化,并利用图形优化获得了设计空间。用透射电镜研究了颗粒的形貌。使用Franz diffusioncell进行体外药物释放研究。固体脂质的量、固体脂质与总脂质的比率和表面活性剂的浓度被发现是高风险变量,并且它们对产品质量的影响使用Central复合设计进行了检查,将颗粒大小、颗粒大小分布和%包埋效率作为因变量。优化后的NLC粒径为72.58nm,PDI为0.137,%包封率为78.79%。体外药物释放研究显示药物在24小时内持续释放,并遵循具有斐济扩散机制的Higuchi模型。本研究成功探索了QbD和基于风险的方法开发含伏立康唑的脂质纳米颗粒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Voriconazole Loaded Lipidic Nanoparticles for Ophthalmic Delivery: Development Using QbD Combined with Risk-based Approach
Voriconazole (VRZ) is widely used for fungal keratitis topically. It is sparingly water soluble and has limited permeability which can lead to poor bioavailability. Nanostructured Lipid Carriers (NLCs) are selected as a carrier for voriconazole as they increase solubility while the lipidic character of the formulation facilitates permeation. o To develop a new method of preparation of lipidic nanoparticles o To apply Quality by design and risk-based approach to find variables o To optimize variables and find the design space o To evaluate and characterize the optimized formulation The present study is an attempt to address the challenges in the formulation of NLCs using a high-speed homogenizer. Quality by Design approach was used to find the material attributes and process parameters playing a significant role in the formulation development. Quality Target product profile was prepared, and failure mode and effect analysis was performed for a better understanding of the risks, ways to alleviate risks, and finally, to propose a control strategy. The formulation was optimized by using 3-levels 3-factors central composite design, and design space was obtained by using graphical optimization. The morphology of the particles was studied by using Transmission Electron Microscope. In vitro drug release study was performed using Franz diffusion cell. The amount of solid lipid, solid lipid to total lipid ratio, and concentration of surfactant were found to be high risk variables and their effects on the product quality were examined using Central composite design considering particle size, particle size distribution and %entrapment efficiency as dependent variables. Optimized NLC had a particle size of 72.58 nm with PDI 0.137 and %entrapment efficiency of 78.79%. The in vitro drug release study showed sustained drug release over the period of 24 hrs and followed the Higuchi model with a fickian diffusion mechanism The present study successfully explored QbD along with Risk-based approach for the development of voriconazole containing lipidic nanoparticles.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Nanomedicine
Current Nanomedicine Medicine-Medicine (miscellaneous)
CiteScore
2.00
自引率
0.00%
发文量
15
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信